Roche Holding stock heads into the open after a 2.2 percent gain
Published on 09/22/2026 at 07:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding stock closed at CHF 372.80 on the SIX Swiss Exchange on September 21, 2026, up 2.2 percent from the prior session. The gain followed European Commission approval for Susvimo, as StockTitan reported on September 21, 2026.
September 21, 2026 in numbers
Roche Holding AG (ISIN CH0012032048) finished at CHF 372.80 on SIX on September 21, 2026, after opening at CHF 359.00. The shares gained 2.2 percent, while the SMI rose 1.1 percent in the same session, giving Roche a 1.1 percentage-point advantage over the reference index.
The move followed the European Commission approval of Susvimo for neovascular age-related macular degeneration. The company release said the decision was announced on September 21, 2026, and described the approval as an expansion of the treatment option in ophthalmology.
Susvimo approval shapes today
The European regulatory decision remains the company-specific event for September 22, 2026, with market attention focused on its implications for Roche's ophthalmology portfolio. The next session on SIX is the reference trading session for the Swiss-listed shares.
